<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413268</url>
  </required_header>
  <id_info>
    <org_study_id>NTP1</org_study_id>
    <nct_id>NCT02413268</nct_id>
  </id_info>
  <brief_title>Topical Nitroglycerin To Prevent Radial Artery Occlusion After Transradial Access: NTP-RAO Trial</brief_title>
  <acronym>NTP-RAO</acronym>
  <official_title>Topical Nitroglycerin To Prevent Radial Artery Occlusion After Transradial Access: NTP-RAO Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Total Cardiovascular Solutions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Total Cardiovascular Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized comparison of topical nitroglycerin versus placebo gel for prevention of radial&#xD;
      artery occlusion after transradial catheterization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients and Methods:&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
      1: All &gt; 18 years old patients referred for transradial coronary angiography.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        1. Absence of informed consent.&#xD;
&#xD;
        2. Known allergy to nitroglycerin.&#xD;
&#xD;
        3. Ad-hoc PCI&#xD;
&#xD;
        4. Previous ipsilateral TRA.&#xD;
&#xD;
        5. Warfarin or NOAC therapy.&#xD;
&#xD;
        6. Systolic blood pressure &lt; 100 mmHg.&#xD;
&#xD;
        7. Critical aortic stenosis (AVA &lt; 0.6 sq.cm)&#xD;
&#xD;
        8. Inability to administer unfractionated heparin.&#xD;
&#xD;
        9. Need for post-procedural use of heparin (UFH, LMWH)&#xD;
&#xD;
       10. Raynaud's disease.&#xD;
&#xD;
       11. Sheathless technique or use of &gt; 11 cm sheath.&#xD;
&#xD;
       12. History of intractable headache of any cause OR Migraine headache.&#xD;
&#xD;
      Transradial Access and Procedure: After routine preparation and sterile draping, the skin of&#xD;
      the distal flexor aspect of the forearm was infiltrated with 1-2 ml of preservative free 1%&#xD;
      lidocaine, 2-3 fingerbreaths above the styloid process. Radial pulse was palpated at that&#xD;
      site and radial artery access was obtained using a 20-gauge teflon sheathed needle after&#xD;
      which a 0.021&quot; guide wire was placed through the teflon cannula into the radial artery lumen,&#xD;
      once continuous blood flow was visualized. A 5 french, 11 cm hydrophilic introducer sheath&#xD;
      (Radiofocus, Terumo Medical) with outer diameter of 2.65 mm will be placed over the guide&#xD;
      wire into the radial artery. 2.5 mg of Verapamil and 200 mcg of nitroglycerin were&#xD;
      administered via the introducer sheath in an intraarterial fashion. Other equipment will be&#xD;
      used as per operator's discretion.&#xD;
&#xD;
      After completion of diagnostic coronary or peripheral angiography, the patients will be&#xD;
      randomized to either &quot;Traditional Hemostasis Group&quot; or &quot;Nitropaste Hemostasis Group&quot; using&#xD;
      sealed envelope technique (SNOSE). Block randomization will be used for each location.&#xD;
&#xD;
      Hemostasis technique:&#xD;
&#xD;
      Control Group: An inflatable band (TR band, Terumo Medical) will be applied at the radial&#xD;
      access site and inflated to obtain hemostasis. Patent hemostasis was attempted in all&#xD;
      patients, using the technique described earlier (10). Status of radial artery flow during&#xD;
      hemostatic compression will be evaluated at the time of onset of hemostasis, and removal of&#xD;
      the band. Duration of compression will be a minimum of 2 hours and upto the operator's&#xD;
      discretion.&#xD;
&#xD;
      Nitropaste Group: An inflatable band (TR band, Terumo Medical) will be applied at the radial&#xD;
      access site after 0.5 inch aliquot of 2% nitroglycerin ointment is applied uniformly on the&#xD;
      surface of the balloon to be in contact with the patients skin. Patent hemostasis will be&#xD;
      attempted in all patients, using the technique described earlier (10). Status of radial&#xD;
      artery flow during hemostatic compression will be evaluated at the time of onset of&#xD;
      hemostasis, and removal of the band. Duration of compression will be a minimum of 2 hours and&#xD;
      upto the operator's discretion.&#xD;
&#xD;
      Radial Artery Patency: Radial artery patency after removal of the band and at the time of&#xD;
      discharge or 2 hours after removal of the band, whichever comes earlier, will be assessed&#xD;
      using reverse Barbeau's test using plethysmographic technique. Ultrasonography will be left&#xD;
      upto the operator's discretion.&#xD;
&#xD;
      Primary Study Endpoint:&#xD;
&#xD;
      1: Absence of radial artery antegrade flow as assessed by absence of plethysmographic signal&#xD;
      in the index finger after occlusive compression of ipsilateral ulnar artery.&#xD;
&#xD;
      Secondary endpoint:&#xD;
&#xD;
        1. Occurrence of new headache&#xD;
&#xD;
        2. Occurrence of hypotension ( systolic blood pressure &lt; 100 mmHg).&#xD;
&#xD;
      Sample Size Calculation:&#xD;
&#xD;
      Based on the published evidence, 11.3% incidence of RAO at 24 hours after band removal has&#xD;
      been observed (Dharma ). Assuming a similar incidence at the time of discharge (&lt; 2 hours&#xD;
      after band removal), and a 50% reduction in the primary study endpoint of RAO detected by&#xD;
      plethysmography, 1168 patients will need to be randomized, 584 patients in each group, to&#xD;
      have a 90% chance of accurately evaluating the difference between the control and treatment&#xD;
      arm, using superiority design with an alpha of 5% (10). A cross-over rate of 10% has been&#xD;
      used in this calculation. Intent-to-treat and per protocol analyses will be performed,&#xD;
      although intent-to-treat analysis will be the primary analysis. Interim analysis will be&#xD;
      performed after 600 patients are randomized to assess the safety of either strategy, by a 3&#xD;
      member data monitoring group.&#xD;
&#xD;
      Statistical Analysis Plan:&#xD;
&#xD;
      Data will be expressed in number (percentage) for categorical variables, and as mean ±&#xD;
      standard deviation for continuous variables (if normally distributed) or as median ±&#xD;
      inter-quartile range (if non-normally distributed). The total study cohort will be&#xD;
      categorized into &quot;Control Group&quot; and &quot;NTP Group&quot;. Continuous variables will be compared&#xD;
      between these 2 groups using student 't' test (if normally distributed) or the Wilcoxon&#xD;
      rank-sum test (if non-normally distributed). Categorical variables were compared using&#xD;
      chi-squared test or Fischer's exact test as appropriate. Multivariable analyses will be&#xD;
      performed to identify predictors of RAO.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radial Artery Occlusion</measure>
    <time_frame>up to 2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache</measure>
    <time_frame>up to 4 hours</time_frame>
    <description>Pain in the head that is new-onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>up to 4 hours</time_frame>
    <description>Systolic blood pressure &lt; 90 mmHg that is new-onset</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Total Atherosclerotic Occlusion of Radial Artery</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient receives an antibiotic ointment with no vasoactive drug as a placebo for comparison.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitropaste</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nitroglycerin 2% ointment is applied above the compression surface on the skin, to evaluate its efficacy in reducing radial artery occlusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin</intervention_name>
    <arm_group_label>Nitropaste</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Nitropaste</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients referred for cardiac catheterization.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1: Absence of informed consent. 2: Known allergy to nitroglycerin. 3: Ad-hoc PCI 4:&#xD;
             Previous ipsilateral TRA. 5: Warfarin or NOAC therapy. 6: Systolic blood pressure &lt;&#xD;
             100 mmHg. 7: Critical aortic stenosis (AVA &lt; 0.6 sq.cm) 8: Inability to administer&#xD;
             unfractionated heparin. 9: Need for post-procedural use of heparin (UFH, LMWH) 10:&#xD;
             Raynaud's disease. 11: Sheathless technique or use of &gt; 11 cm sheath. 12: History of&#xD;
             intractable headache of any cause OR Migraine headache.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tejas M Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apex Heart Institute, Ahmedabad, India</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tejas M Patel, MD</last_name>
    <email>theheartworld@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Apex Heart Institute</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tejas M Patel, MD</last_name>
      <email>theheartworld@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yash Soni</last_name>
      <email>theheartworld@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 6, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>September 14, 2019</last_update_submitted>
  <last_update_submitted_qc>September 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Total Cardiovascular Solutions</investigator_affiliation>
    <investigator_full_name>Dr. Tejas M. Patel, MD</investigator_full_name>
    <investigator_title>Chairman</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

